. 2016 Apr 26;5(1):105–109. doi: 10.1007/s40123-016-0049-3

Table 1.

Patient demographics and baseline values

Patient number	Gender	Age	Diabetes type	Eye number	Left or right eye	IOP-lowering drops	Prior medical treatment for DME			Date of 0.2 μ/g day FAc implant
Patient number	Gender	Age	Diabetes type	Eye number	Left or right eye	IOP-lowering drops	Laser	RBZ	IVTA	Date of 0.2 μ/g day FAc implant
1	Male	70	II	1	LE	N	1× Grid	9×	1×	July 29, 2014
1	Male	70	II	2	RE	N	1× Grid	9×	1×	September 9, 2014
2	Female	58	II	3	RE	Lumigan/azarga	1× Focal	19×	1×	June 10, 2014
2	Female	58	II	4	LE	Lumigan/azarga	2× Focal	19×	1×	September 23, 2014
3	Male	44	I	5	RE	Latanoprost/timolol	1× Grid	6×	3×	July 25, 2014
3	Male	44	I	6	LE	Latanoprost/timolol	1× Grid	6×	2×	October 30, 2014
4	Male	82	II	7	RE	N	1× Grid	3×	2×	April 10, 2014
4	Male	82	II	8	LE	N	1× Grid	3×	1×	July 11, 2014
5	Male	63	I	9	LE	N	1× Grid	6×	0	July 18, 2014
5	Male	63	I	10	RE	N	1× Grid	9×	0	October 21, 2014

DME diabetic macular edema, FAc fluocinolone acetonide, IOP intraocular pressure, IVTA intravitreal triamcinolone, LE left eye, RE right eye, RBZ ranibizumab